This article demonstrates that overproduction of p62 or a deficiency in autophagy competed with NRF2KEAP1 interaction and activated NRF2
Tirzepatide (Zepbound, Mounjaro) This is a dual-agonist medication, meaning it targets both GLP-1 and GIP receptors
11 In April 2026 the FDA removed BPC-157 (along with several other peptides) from that interim list, but it is important to read that move correctly: it was a procedural step tied to withdrawn nominations and a fresh review under the Section 503A framework, not a finding that the compound is safe or effective, and it did not add BPC-157 to the positive list of substances sanctioned for compounding
There appears to be no obvious conflict between studies surrounding the mechanisms of BPC 157
This additional indication was based on results from a multinational clinical trial showing that Wegovy reduced the risk of major adverse cardiovascular events (MACE) by 20%
Hydrate first , because dehydration can feel like fatigue